StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CHRS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.61 | $1.57 | -2.48% | 1.5M |
| 05-18 | $1.57 | $1.49 | -5.10% | 1.8M |
| 05-19 | $1.49 | $1.48 | -0.67% | 1.4M |
| 05-20 | $1.47 | $1.51 | +2.72% | 0.7M |
| 05-21 | $1.49 | $1.59 | +6.71% | 0.9M |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2019 2019-12-31 | Annual 2019 2019-09-30 | Annual 2019 2019-06-30 | Annual 2019 2019-03-31 |
|---|---|---|---|---|
Revenue | $123.86M | $111.68M | $83.43M | $37.10M |
Operating Income | $107.77M | $62.73M | $10.89M | $-16.60M |
Net Income | $89.83M | $50.61M | $23.57M | $-20.00M |
EPS (Diluted) | $1.23 | $0.69 | $0.05 | $-0.29 |
Total Assets | $408.93M | $327.38M | $240.46M | $186.12M |
Total Liabilities | $303.71M | $271.36M | $244.44M | $224.63M |
Cash & Equivalents | $177.67M | $165.12M | $105.93M | $81.52M |
Free Cash Flow OCF − CapEx | $26.53M | $9.21M | $-44.82M | $-57.32M |
Shares Outstanding | 70.37M | 72.87M | 72.28M | 69.14M |
CHRS is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.